HB1871 establishes a Maternal Health Monitoring Pilot Program within the Hawaii Department of Health to provide remote patient monitoring for pregnant Medicaid recipients enrolled in participating managed care organizations who have maternal hypertension or maternal diabetes. The program would use FDA-authorized devices to collect and transmit health data such as blood pressure, weight, and blood glucose, and would pair participants with a remote monitoring clinical care team of licensed nurses and dietitians for monitoring, coaching, and postpartum support. The pilot is limited to up to 300 eligible participants across as many counties as needed, must begin within 180 days after the contract is executed, and would run for two years after becoming operational or until December 27, 2029, whichever comes first.
The bill also requires the Department of Health to select participating managed care organizations and a technology vendor, with the managed care organizations contracting directly with the vendor and ensuring participant access. The vendor must provide devices, training, a program manager, and an escalation pathway for concerning readings that require additional medical review. The bill includes a $600,000 allocation to offset pilot costs and directs the department to pay an administration fee to the participating managed care organizations to cover contracting and program administration. It also requires a formal evaluation report after 24 months, using claims, vital statistics, and electronic health record data to assess maternal, fetal, neonatal outcomes and potential Medicaid savings, and to recommend whether the program should be expanded statewide.
In terms of legal impact, the bill creates a new temporary program within the Department of Health rather than permanently changing existing Medicaid or health care statutes. It affects the department, participating managed care organizations, technology vendors, and in-network obstetric and maternal-fetal medicine providers serving pregnant Medicaid beneficiaries. The bill also authorizes state spending for the pilot and requires the department to report findings to the governor and legislative leaders, which could inform future policy or broader adoption if the pilot shows positive results.
The general sentiment reflected in the available legislative history appears supportive. The Senate Health and Human Services Committee passed the bill with amendments on a 4-0 vote, and the measure advanced with no recorded opposition in the provided materials. The absence of transcript discussion limits insight into detailed debate, but the committee action suggests broad agreement on the value of testing remote monitoring as a maternal health intervention.
The main points of potential contention are likely to be fiscal and implementation-related rather than ideological. The bill requires state funding, coordination among the department, managed care organizations, and a private technology vendor, and it sets detailed operational requirements for device delivery, training, monitoring, and escalation. Questions may also arise about whether the pilot’s limited size and delayed effective date will produce meaningful results, how data privacy and interoperability will be managed, and whether the program should be expanded if the evaluation shows benefits.
HB1871 would add a new Department of Health-administered maternal health pilot program focused on remote monitoring for pregnant Medicaid recipients with hypertension or diabetes. It authorizes state funding, requires contracts with managed care organizations and a technology vendor, and mandates a post-pilot evaluation using health and claims data. The bill does not broadly amend existing health statutes, but it creates new administrative duties, spending authority, and reporting requirements that could shape future Medicaid and maternal health policy.
The available voting history indicates favorable sentiment toward the bill. The Senate Health and Human Services Committee approved it unanimously, 4-0, with amendments, and it subsequently advanced to Ways and Means. No committee testimony or transcript excerpts were provided, so the record shows support but not detailed debate. Overall, the bill appears to have been received as a practical maternal health initiative rather than a controversial policy change.
The likely areas of contention are cost, program design, and administrative complexity. The bill requires a $600,000 allocation and a fee structure to cover vendor and managed care organization administration, which may prompt scrutiny over whether the pilot is adequately funded. Legislators may also question the effectiveness of a small pilot limited to 300 participants, the feasibility of coordinating among the department, managed care organizations, and a vendor, and the handling of sensitive medical data. If any opposition exists, it would most likely focus on implementation logistics and fiscal oversight rather than the underlying goal of improving maternal outcomes.